A panel of experts discussed decentralized web and Web3 technology — and its potential for impacting communities. Photo courtesy of DivInc

Houston innovators dispelled some of the misconceptions about the decentralized web and Web3 technology at a recent Ion panel, highlighting the technology’s ability to bring communities together.

DivInc, a Texas-based accelerator focused on helping BIPOC and female founders on their entrepreneurial journeys, hosted a panel to discuss the benefits of transitioning to DWeb for entrepreneurs, personal success stories of using Web3 technology, and promoted its inaugural DWeb for Social Impact Accelerator.

The panelists included Giorgio Villani, founder of Spindletop Digital; Akeel Bernard, community development manager of Impact Hub Houston; and Ayoola John, co-founder and CEO of Astronaut. The discussion was moderated by Cherise Luter, marketing director of DivInc.

With the application for the DWeb 12-week accelerator program live, announced earlier this year, Luter says the panel was initiated to help explain the links between impact entrepreneurship and DWeb, two areas that people may think are very separate.

“This is our first time hosting a social impact accelerator here in Houston and we’re really excited about it. We added this extra piece of Web3, DWeb – how social entrepreneurs are utilizing this new technology to push forward their vision and bring about their startups,’” Luter says.

Villani, a founder of multiple companies that employ Web3 innovation, defined this technology as a tool of decentralization in which users are responsible for their own data and transactions are kept transparent by being publicly accessible. Villani contrasted this setup to the modern internet, known as Web2, in which users entrust third parties with encrypting their personal data, allowing them to mine and profit from this information.

“Web3 is a flipping of the script a little bit – it’s where we’re focusing primarily on the individual, where the individual is being empowered. Everybody manages their own keys and you don’t have to trust a third party to do anything within the system … you don’t have to cede your power to third party entities – it’s really an empowering thing to do,” Villani explains.

Villani addressed the misunderstanding that the decentralized web is too complicated for the average person to use by highlighting his partnership with multimedia Houston artist J. Omar Ochoa. Ochoa is incorporating Web3 technologies like AI and NFTs into an exhibit, allowing him to interact directly with buyers.

“The misconception is that (Web3) is difficult or too technical and it’s really not. There’s some stuff that takes a little bit of work but once you’ve done that the whole world of Web3 opens up in front of you,” Villani says.

For Villani, Web3 technologies are about the opportunity for connection.

“When you look around you, a lot of people these days are lonely and it’s funny because we have these platforms like Facebooks, Instagrams, WhatsApps, Snapchats and they’re all designed to bring us together but if you really look around you we’re not together,” Villani explains. “For me fundamentally, we have to reimagine how we build social networks, how we connect people.”

Web3 technologies are not all inherently about decentralization of the internet so much as rethinking how to rebuild the web to bring people together based on shared interests, adds John, co-founder of a social impact company that uses Web3 to help brands build online communities.

In contrast to much of the tech world, John also says that NFTs and cryptocurrencies, both of which are considered Web3 tools as they operate on blockchains, are not components of DWeb because they are tied up by monopolies. As the majority of NFTs are sold on one website and Bitcoin continues to dominate the cryptocurrency market, John explains they can not qualify as decentralized.

“I believe I can make an argument that crypto at its core is not about decentralization. What I believe crypto is and the Web3 movement is about reimagination,” John shares.

Bernard, who works directly with social impact entrepreneurs at Impact Hub Houston, says he anticipates founders looking to secure investors for their DWeb related companies will struggle, at first, because they must concisely explain the technology and business model at play. Bernard says he previously coached entrepreneurs on how to explain to investors that investing in social impact companies is not charity but a typical investment that will pay returns. Bernard expects DWeb focused companies will face similar uphill battles of getting investors to understand their concepts.

“I think with DWeb because it’s a newer network it’s going to require social impact entrepreneurs to educate investors and also users on the benefits of DWeb,” Bernard explains. “You’re going to have to be able to explain to them in a clear and consistent way especially to the investors, folks that have the means but don’t understand what DWeb is, how it can be utilized for success.”

Photo courtesy of DivInc

DivInc has announced a new program that will support BIPOC and women founders of social enterprise startups working on Web3 technology. Photo via divinc.org

Texas nonprofit introduces newest accelerator to be hosted in Houston this fall

apply now

A Texas accelerator that's focused on supporting traditionally marginalized entrepreneurs has announced its newest program.

DivInc has introduced DWeb for Social Impact Accelerator, a new program set to support BIPOC and women founders of social enterprise startups developing global solutions with DWeb and Web3 technologies — such as blockchain, crypto-asset, artificial intelligence, machine learning, augmented reality, and more.

The first cohort of the program, which is supported by the Filecoin Foundation for the Decentralized Web, or FFDW, will run from September through November at the Ion. Applications are open now.

"Through the DWeb for Social Impact Accelerator we are marrying activism with the decentralized web in a way that builds these startups and puts them at the forefront of solving society's toughest challenges," says Preston James, CEO at DivInc, in a news release. "We want to see our creative tech economy founders playing a major role in building and benefiting from DWeb and Web3 for the greater good. This partnership with FFDW is a huge leap forward in that pursuit."

The 12-week accelerator will support up to 10 companies, and, at the end of the program, each selected company will receive $10,000 in non-dilutive seed funding. In addition to FFDW, the program is supported by Houston Premier Partners, J.P. Morgan Chase & Co., Verizon, The Ion, and Mercury.

"A core part of FFDW's mission is education about the decentralized web," says Marta Belcher, president and chair of Filecoin Foundation for the Decentralized Web, in the release. "FFDW is absolutely thrilled to bring more diverse voices into the Web3 ecosystem."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”